$7.70−0.48 (−5.87%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Verastem (VSTM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
11 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~97.0%/yr (FY21→FY25), net margin −677.6%. Worth your attention in FY25: Share count (+376.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲209.1%
30.9
FY21→FY25CAGR +97.0%/yr
Net income ($M)▼60.3%
−209.5
FY21→FY25CAGR —
Free cash flow ($M)▼31.2%
−137.5
FY21→FY25CAGR —
Diluted EPS▲17.5%
−3.02
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+376.8%
14.5mn → 69.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$0.0K
−100.0% YoY in FY25 · 0.0% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-678¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -677.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6846, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 100,296.0 | 30,914.0 | 10,000.0 | 0.0 | 2,596.0 | 2,053.0 | ▲209.1% | +97.0% |
Cost of revenue | 12,812.0 | 4,600.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 87,484.0 | 26,314.0 | —A | —A | —A | —A | — | — |
Research & development | 180,034.0 | 114,599.0 | 81,334.0 | 61,356.0 | 50,558.0 | 39,347.0 | ▲40.9% | +30.6% |
Selling, general & admin | 100,640.0 | 81,146.0 | 43,622.0 | 30,728.0 | 24,975.0 | 24,115.0 | ▲86.0% | +35.4% |
Total operating expenses | 281,791.0 | 196,443.0 | 124,956.0 | 92,084.0 | 75,533.0 | 63,462.0 | ▲57.2% | +32.6% |
Operating incomefeeds ROC rank | −194,307.0 | −170,129.0 | −114,956.0 | −92,084.0 | −72,937.0 | −61,409.0 | ▼48.0% | — |
Other income, net | 16,180.0 | −39,342.0 | −15,496.0 | 4,717.0 | −875.0 | −9,791.0 | — | — |
Pretax income | −178,127.0 | −209,471.0 | −130,452.0 | −87,367.0 | −73,812.0 | −71,200.0 | ▼60.6% | — |
Income tax | — | 0.0 | 185.0 | 0.0 | 0.0 | — | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −178,903.0 | −209,471.0 | −130,637.0 | −87,367.0 | −73,812.0 | −71,200.0 | ▼60.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.64 | −3.02 | −3.66 | −3.96 | −4.57 | −4.90 | ▲17.5% | — |
Diluted shares (mn) | 101.24 | 69.31 | 35.71 | 22.05 | 16.14 | 14.54 | ▲94.1% | +47.8% |
| Margins | ||||||||
Gross margin81st pct in Healthcare | 87.2% | 85.1% | —A | —A | —A | —A | — | — |
Operating margin | −193.7% | −550.3% | −1149.6% | — | −2809.6% | −2991.2% | ▲599.2pp | — |
Net margin8th pct in Healthcare | −178.4% | −677.6% | −1306.4% | — | −2843.3% | −3468.1% | ▲628.8pp | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-04 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Verastem's revenue last fiscal year?
Verastem reported revenue of $30.9M in fiscal 2025, up 209.1% from fiscal 2024.
What was Verastem's net income?
Verastem reported net income of −$209.5M in fiscal 2025, a net margin of −677.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

